Indication
Treatment of adults with moderate-to-severe prurigo nodularis (PN) who are candidates for systemic therapy.
Medicine details
- Medicine name:
- dupilumab (Dupixent)
- SMC ID:
- SMC2598
- Pharmaceutical company
- Sanofi
- BNF chapter
- Skin
- Submission type
- Full
- Publication due date:
- 12 February 2024
- SMC meeting date:
- 09 January 2024
- Patient group submission deadline:
- 06 November 2023